Buysiders say Amgen Inc.'s aggressive opening offer for Onyx Pharmaceuticals Inc. may have dissuaded other would-be suitors from entering into a bidding war.

On Aug. 25 the companies agreed to a purchase price of $125 per share in cash, or about $10.4 billion.